These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 24164828

  • 1. Empiric switch from calcineurin inhibitor to sirolimus-based immunosuppression in pediatric heart transplantation recipients.
    Loar RW, Driscoll DJ, Kushwaha SS, Cramer CH, O'Leary PW, Daly RC, Mauriello DA, Johnson JN.
    Pediatr Transplant; 2013 Dec; 17(8):794-9. PubMed ID: 24164828
    [Abstract] [Full Text] [Related]

  • 2. Calcineurin inhibitor minimization using sirolimus leads to improved renal function in pediatric heart transplant recipients.
    Chinnock TJ, Shankel T, Deming D, Cutler D, Sahney S, Fitts J, Chinnock RE.
    Pediatr Transplant; 2011 Nov; 15(7):746-9. PubMed ID: 21883751
    [Abstract] [Full Text] [Related]

  • 3. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.
    J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861
    [Abstract] [Full Text] [Related]

  • 4. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ.
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [Abstract] [Full Text] [Related]

  • 5. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P, Neves M, Santos L, Macário F, Alves R, Mota A.
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [Abstract] [Full Text] [Related]

  • 6. Indications, tolerance and complications of a sirolimus and calcineurin inhibitor immunosuppression regimen: intermediate experience in pediatric heart transplantation recipients.
    Matthews K, Gossett J, Kappelle PV, Jellen G, Pahl E.
    Pediatr Transplant; 2010 May; 14(3):402-8. PubMed ID: 20214748
    [Abstract] [Full Text] [Related]

  • 7. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
    Potter BJ, Giannetti N, Edwardes MD, Cecere R, Cantarovich M.
    Clin Transplant; 2007 May; 21(3):305-8. PubMed ID: 17488377
    [Abstract] [Full Text] [Related]

  • 8. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.
    Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429
    [Abstract] [Full Text] [Related]

  • 9. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA.
    Liver Transpl; 2007 Dec 27; 13(12):1694-702. PubMed ID: 18044728
    [Abstract] [Full Text] [Related]

  • 10. Increased incidence of acute graft rejection on calcineurin inhibitor-free immunosuppression after heart transplantation.
    Celik S, Doesch AO, Konstandin MH, Kristen AV, Ammon K, Sack FU, Schnabel P, Katus HA, Dengler TJ.
    Transplant Proc; 2011 Jun 27; 43(5):1862-7. PubMed ID: 21693290
    [Abstract] [Full Text] [Related]

  • 11. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity.
    Höcker B, Feneberg R, Köpf S, Weber LT, Waldherr R, Wühl E, Tönshoff B.
    Pediatr Transplant; 2006 Aug 27; 10(5):593-601. PubMed ID: 16856996
    [Abstract] [Full Text] [Related]

  • 12. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 13. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH.
    Transplantation; 2010 Apr 15; 89(7):864-72. PubMed ID: 20061999
    [Abstract] [Full Text] [Related]

  • 14. Long-term effects on renal function of dose-reduced calcineurin inhibitor and sirolimus in cardiac transplant patients.
    Khandhar SJ, Shah HV, Shullo MA, Zomak R, Navoney M, McNamara DM, Kormos RL, Toyoda Y, Teuteberg JJ.
    Clin Transplant; 2012 Apr 15; 26(1):42-9. PubMed ID: 21303417
    [Abstract] [Full Text] [Related]

  • 15. [Sirolimus use in heart transplantation recipients with chronic renal dysfunction].
    Yin D, Huang J, Feng L, Liao ZK, Feng GX, Wang W, Song YH, Hu SS.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Feb 15; 40(2):136-40. PubMed ID: 22490714
    [Abstract] [Full Text] [Related]

  • 16. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A, Zúñiga-Varga J, Correa-Rotter R, Alberú J.
    Transplant Proc; 2009 Dec 15; 41(10):4138-46. PubMed ID: 20005355
    [Abstract] [Full Text] [Related]

  • 17. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients.
    Kaplinsky E, González-Costello J, Manito N, Roca J, Barbosa MJ, Nebot M, Salazar-Mendiguchia J, Berdejo J, Mañas P, Miralles A, Cequier A.
    Transplant Proc; 2012 Nov 15; 44(9):2564-6. PubMed ID: 23146455
    [Abstract] [Full Text] [Related]

  • 18. Rejection after conversion to a proliferation signal inhibitor in chronic heart transplantation.
    González-Vílchez F, Vázquez de Prada JA, Paniagua MJ, Almenar L, Mirabet S, Gómez-Bueno M, Díaz-Molina B, Arizón JM, Delgado J, Pérez-Villa F, Crespo-Leiro MG, Martínez-Dolz L, Roig E, Segovia J, Lambert JL, Lopez-Granados A, Escribano P, Farrero M.
    Clin Transplant; 2013 Nov 15; 27(6):E649-58. PubMed ID: 24025040
    [Abstract] [Full Text] [Related]

  • 19. Calcineurin inhibitor conversion to rapamycin can improve graft function in living donor kidney transplantation with older donors.
    Chen GD, Liu XC, Shi L, Qiu J, Wang CX, Fei JG, Li J, Huang G, Chen LZ.
    Transplant Proc; 2013 May 15; 45(4):1648-50. PubMed ID: 23726640
    [Abstract] [Full Text] [Related]

  • 20. De-novo calcineurin-inhibitor-free immunosuppression with sirolimus and mycophenolate mofetil after heart transplantation: 5-year results.
    Meiser B, Buchholz S, Kaczmarek I.
    Curr Opin Organ Transplant; 2011 Oct 15; 16(5):522-8. PubMed ID: 21836511
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.